Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Apogee Therapeutics ( (APGE) ) has shared an announcement.
On July 7, 2025, Apogee Therapeutics announced positive 16-week results from Part A of its Phase 2 APEX clinical trial for APG777, an anti-IL-13 antibody, in moderate-to-severe atopic dermatitis patients. The trial met its primary endpoint with a 71.0% reduction in EASI scores compared to 33.8% for placebo, and demonstrated a favorable safety profile. The results bolster APG777’s potential as a best-in-class treatment, with plans for further trials and a potential commercial launch this decade.
The most recent analyst rating on (APGE) stock is a Buy with a $110.00 price target. To see the full list of analyst forecasts on Apogee Therapeutics stock, see the APGE Stock Forecast page.
Spark’s Take on APGE Stock
According to Spark, TipRanks’ AI Analyst, APGE is a Neutral.
The overall score reflects the company’s early-stage biotech position, with significant financial risks due to no revenue and high cash burn. Positive clinical trial results and a strong cash position are key strengths, but valuation concerns and technical analysis suggest caution.
To see Spark’s full report on APGE stock, click here.
More about Apogee Therapeutics
Apogee Therapeutics is a clinical-stage biotechnology company focused on developing optimized, novel biologics for inflammatory and immunology markets, including atopic dermatitis, asthma, COPD, and eosinophilic esophagitis. The company aims to achieve best-in-class efficacy and dosing through advanced antibody engineering and has a broad pipeline targeting well-established mechanisms of action.
Average Trading Volume: 738,815
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.83B
For an in-depth examination of APGE stock, go to TipRanks’ Overview page.